Intravenous azithromycin plus ceftriaxone followed by oral azithromycin for the treatment of inpatients with community-acquired pneumonia: An open-label, non-comparative multicenter trial

Brazilian Journal of Infectious Diseases

Volumn 12, Issue 3, 2008, Pages 202-209

  Rubio, Fernando Gongora ^a   Cunha, Clóvis A ^b   Lundgren, Fernando L C ^c   Lima, Maria P J S ^d   Teixeira, Paulo J Z ^e   Oliveira, Julio C A ^f   Golin, Valdir ^g   Mattos, Waldo L L D ^h   Mählmann, Herbert K ⁱ   Moreira, Edson D ^j   Jardim, Jose R ^k   Silva, Rodney L F ^l   Silva, Patricia H B ^m  

^a HOSPITAL DE BASE   (Brazil)

^b HOSPITAL NOSSA SENHORA DAS GRAÇAS   (Brazil)

^c Otavio de Freitas General Hospital   (Brazil)

^d PONTIFÍCIA UNIVERSIDADE CATÓLICA DE CAMPINAS   (Brazil)

^e Irmandade da Santa Casa de Misericordia de Porto Alegre   (Brazil)

^f University Hospital   (United States)

^g IRMANDADE DA SANTA CASA DE MISERICÓRDIA DE SÃO PAULO   (Brazil)

^h HOSPITAL NOSSA SENHORA DA CONCEIÇÃO   (Brazil)

ⁱ General Hospital of Itapecerica da Serra OSS Seconci   (Brazil)

^j General Hospital Roberto Santos   (Brazil)

^k FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^l FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^m Sanatorinhos Hospital OSS Ação Comunitária   (Brazil)

more..

Author keywords

Anti bacterial agents; Azithromycin; Community acquired infections; Macrolide ketolides; Pneumonia

Indexed keywords

AZITHROMYCIN; CEFTRIAXONE; CEFUROXIME AXETIL;

ABDOMINAL PAIN; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC RESISTANCE; APHTHOUS STOMATITIS; ARTICLE; BACTERIUM CULTURE; BRAZIL; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EPIGASTRIC PAIN; ERADICATION THERAPY; FEMALE; HAEMOPHILUS INFLUENZAE; HOSPITAL PATIENT; HUMAN; HYPERTENSION; INJECTION SITE BURNING; INJECTION SITE PAIN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PNEUMONIA; PUBLIC HEALTH PROBLEM; SIDE EFFECT; SINGLE DRUG DOSE; STREPTOCOCCUS PNEUMONIAE; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

EID: 54349115481     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1413-86702008000300008     Document Type: Article

References (37)

1. Bartlett J.G., Mundy L.M. Community-acquired pneumonia. N Engl J Med 1995;333(24):1618-24.
2. Fine M.J., Smith M.A., Carson C.A., et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996;275(2):134-41.
3. Marrie T.J., Peeling R.W., Fine M.J., et al. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med 1996;101(5):508-15.
4. Marrie T.J. Community-acquired pneumonia. Clin Infect Dis 1994; 18(4):501-15.
5. Bates J.H., Campbell G.D., Barron A.L., et al. Microbial etiology of acute pneumonia in hospitalized patients. Chest 1992; 101(4):1005-12.
6. Fang G.D., Fine M., Orloff J., et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. Medicine (Baltimore) 1990;69(5):307-16.
7. Brandileone M.C., et al. Increase in numbers of beta-lactam-resistant invasive Streptococcus pneumoniae in Brazil and the impact of conjugate vaccine coverage. Journal of Medical Microbiology 2006; 55:567-74.
8. ATS Statement. Guidelines for the initial management of adults with conmunity-acquired pneumonia: diagnosis assesment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993;148:1418-26.
9. Stahl J.E., Barza M., Desjardin J., et al. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med 1999; 159:2576-80.
10. Lode H. In: Azithromycin in the treatment of community-acquired pneumonia in adults. Cambridge Medical Publications, 2002.
11. Sanchez F., Mensa J., Martinez J.A., et al. Is Azithromycin the First-Choice Macrolide for Treatment of Community-Acquired Pneumonia? Clin Infect Dis 2003;6(10):1239-45.
12. Plouffe J., Schwartz D.B., Kolokathis A., et al. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group. Antimicrob Agents Chemother 2000; 44(7):1796-802.
13. American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assesment of severity, and initial antimicrobial therapy. Am Respir Crit Care Med 2001;163:1730-54.
14. Pereira C.A.C., Rocha R.T., Silva R.F., et al. Diretrizes para Pneumonias Adquiridas na Comunidade (PAC) em Adultos Imunocompetentes. J Bras Pnem 2004;30(Supl)4:11-4.
15. Bartlett J.G., Dowell S.F., Mandell L.A., et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000;31(2):347-82.
16. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clin Infect Dis 2007;44 Suppl 2:S27-72.
17. Heffelfinger J.D., Dowell S.F., Jorgensen J.H., et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000;160(10):1399-8.
18. Rifenburg R.P., Paladino J.A., Bhavnani S.M., et al. Influence of fluoroquinolone purchasing patterns on antimicrobial expenditures and Pseudomonas aeruginosa susceptibility. Am J Health Syst Pharm 1999;56(21):2217-23.
19. Park-Wyllie L.Y., Juurlink D.N., Kopp A., et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006; 354:1352-61.
20. Metersky M.L., Ma A., Houck P.M., Bratzler D.W. Antibiotics for bacteremic pneumonia. Chest 2007;131:466-73.
21. Chen D.K., McGeer A., de Azavedo J.C., Low D.E. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 1999; 341(4):233-9.
22. Garey K.W., Amsden G.W. Intravenous azithromycin. Ann Pharmacother 1999;33(2):218.
23. Fine M.J., Singer D.E., Hanusa B.H., et al. Validation of a pneumonia prognostic index using the MedisGroups Comparative Hospital Database. Am J Med 1993;94(2):153-9.
24. Mandell L.A., Bartlett J.G., Dowell S.F., et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003;37:1405.
25. File T.M. Community-acquired pneumonia. Lancet 2003;362:1991.
26. Mills G.D., Oehley M.R., Arrol B. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: metaanalysis. BMJ 2005;330:456.
27. Shefet D., Robenshtock E., Paul M., Leibovici L. Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults. Cochrane Database Syst Rev 2005:CD004418.
28. Mandell L.A., Marrie T.J., Grossman R.F., et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian infectious diseases society and the Canadian thoracic society. Clin Infect Dis 2000;31:383-421.
29. Mortensen E.M., Restrepo M., Anzueto A., Pugh J. Effects of guideline-concordant antimicrobial therapy on mortality among patients with community-acquired pneumonia. Am J Med 2004;117:726.
30. Menendez R., Torres A., Zalacain R., et al. Guidelines for the treatment of community-acquired pneumonia: Predictors of adherence and outcome. Am J Respir Crit Care Med 2005;172:757.
31. Stahl J.E., Barza M., DesJardin J., et al. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med 1999; 159(21):2576-80.
32. Gleason P.P., Meehan T.P., Fine J.M., et al. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999; 159(21):2562-72.
33. Martinez J.A., Horcajada J.P., Almela M., et al. Addition of a macrolide to a beta-lactam-based empiric antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003;36:389.
34. Waterer G.W., Somes G.W., Wunderink R.G. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001;161:1837.
35. Sanchez F., Mensa J., Martinez J.A., et al. Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia? Clin Infect Dis 2003;36(10):1239-45.
36. Bohte R., van't Wout J.W., Lobatto S., et al. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1995;14(3):182-7.
37. Paladino J.A., Gudgel L.D., Forrest A., Niederman M.S. Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs. cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia. Chest 2002;122(4):1271-9.